Pembrolizumab found to be safe with durable responses in advanced non-small cell lung cancer

PARP inhibitor combo shows early promise for patients with and without BRCA mutations

Phase III trial shows pembrolizumab preferable to ipilimumab in advanced melanoma

Long-term, regular aspirin use modestly decreased cancer risk

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

US breast cancer cases expected to increase by as much as 50 percent

Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer

DNA stool test recommended as screening tool for colon cancer

New immunotherapy yields long-lasting responses in some patients with advanced melanoma

How is ganetespib regulating the response of tumour cells in lung cancer?

Extended overnight fasting may lead to reduced breast cancer risk

Incidences of liver cancer rising in the USA